These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 6210878

  • 21. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH, Yates AJ, Gray RE, Hamdy NA, McCloskey EV, Preston FE, Greaves M, Neil FE, Kanis JA.
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [Abstract] [Full Text] [Related]

  • 22. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
    Douglas DL, Duckworth T, Kanis JA, Preston C, Beard DJ, Smith TW, Underwood I, Woodhead JS, Russell RG.
    Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
    Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmström T.
    Lancet; 1983 Jan 22; 1(8317):146-9. PubMed ID: 6130197
    [Abstract] [Full Text] [Related]

  • 25. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS.
    Lancet; 1980 May 17; 1(8177):1043-7. PubMed ID: 6103389
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treatment with clodronate in patients with hypercalcemia secondary to malignancy.
    Lind L, Wengle B, Ljunghall S.
    Ups J Med Sci; 1987 May 17; 92(3):259-63. PubMed ID: 2966487
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton.
    Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghé F, Pannuti F.
    Oncology; 1991 May 17; 48(2):97-101. PubMed ID: 1825515
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Interaction of dichloromethylene diphosphonate and vitamin D on bone of thyroparathyroidectomized rats.
    Weisbrode SE, Capen CC, Pendley CB.
    Am J Pathol; 1977 Oct 17; 89(1):137-52. PubMed ID: 143891
    [Abstract] [Full Text] [Related]

  • 34. [Monotherapy with clodronate for tumor-induced hypercalcemia].
    Harjung H, Fritze D.
    Dtsch Med Wochenschr; 1990 Jan 12; 115(2):48-52. PubMed ID: 2136827
    [Abstract] [Full Text] [Related]

  • 35. [Neoplastic hypercalcemia with renal insufficiency: treatment with dichloromethylene diphosphonate].
    Conte N, Di Virgilio R, Roiter I, Foscolo G, Baruffi C.
    Clin Ter; 1985 Nov 15; 115(3):177-80. PubMed ID: 2935356
    [No Abstract] [Full Text] [Related]

  • 36. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 15; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M, de Vernejoul MC, Brière M, Miravet L, Clavel B.
    Presse Med; 1984 Feb 25; 13(8):483-6. PubMed ID: 6230630
    [Abstract] [Full Text] [Related]

  • 39. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE.
    Calcif Tissue Int; 2007 Nov 25; 81(5):341-51. PubMed ID: 17874331
    [Abstract] [Full Text] [Related]

  • 40. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.